Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 641 to 650 of 2443 total matches.
A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B)
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
hepatitis B component as Engerix-B
and is licensed for use only in adults. 1
Table 1. Hepatitis B Vaccines ...
The FDA has approved a two-dose hepatitis B virus
(HBV) vaccine (Heplisav-B – Dynavax) for use in adults
≥18 years old. The three other HBV vaccines marketed
in the US are usually administered in 3 doses. Engerix-B
and Recombivax HB are licensed for use in persons of
all ages. A combination hepatitis A/B vaccine (Twinrix)
contains the same hepatitis B component as Engerix-B
and is licensed for use only in adults.
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes ...
The FDA has approved semaglutide (Ozempic – Novo
Nordisk), a long-acting injectable GLP-1 (glucagon-like
peptide-1) receptor agonist, for once-weekly
treatment of adults with type 2 diabetes. It is the sixth
GLP-1 receptor agonist to be approved in the US.
L-Glutamine (Endari) for Sickle Cell Disease
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
),
hospitalizations for sickle cell pain (median 1.0/year
vs 2.4/year with placebo), and patients who required ...
The FDA has approved an oral powder formulation
of the amino acid L-glutamine (Endari – Emmaus) to
reduce the acute complications of sickle cell disease
in patients ≥5 years old. Endari is only the second
drug to be approved for use in sickle cell disease; the
antimetabolite hydroxyurea (Droxia) was approved
20 years ago. L-glutamine oral powder is also
available by prescription as NutreStore for treatment
of short bowel syndrome and over the counter as a
dietary supplement.
In Brief: Olmesartan and Sprue-Like Enteropathy
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
significant difference. Whether
Table 1. Pharmacology
Class Tyrosine kinase inhibitor
Formulation 40 mg ...
A reader asked whether healthcare providers should avoid prescribing the angiotensin receptor blocker (ARB) olmesartan medoxomil (Benicar, and others) because it can cause severe GI adverse effects.In 2013, the FDA warned that olmesartan can cause sprue-like enteropathy, a condition characterized by intestinal villous atrophy, severe chronic diarrhea, and significant unintended weight loss. The warning was based on 23 cases of serious sprue-like enteropathy associated with use of olmesartan, some occurring years after starting the drug. All patients improved after stopping olmesartan; 10 had a...
Neratinib (Nerlynx) for HER2-Positive Breast Cancer
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
significant difference. Whether
Table 1. Pharmacology
Class Tyrosine kinase inhibitor
Formulation 40 mg ...
The FDA has approved the oral tyrosine kinase
inhibitor neratinib (Nerlynx – Puma Biotechnology)
for extended adjuvant treatment of adults with early-stage,
human epidermal growth factor receptor 2
(HER2)-positive breast cancer, following adjuvant
trastuzumab (Herceptin)-based therapy. HER2 is
overexpressed in about 20% of breast cancers. Up
to 30% of early-stage, HER2-positive breast cancer
cases treated with trastuzumab-based adjuvant
therapy recur.
In Brief: Severe Hypersensitivity Reactions with Rolapitant IV Emulsion (Varubi)
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
that the IV emulsion formulation of
the substance P/neurokinin 1 (NK1) receptor antagonist
rolapitant ...
The FDA has warned that the IV emulsion formulation of the substance P/neurokinin 1 (NK1) receptor antagonist rolapitant (Varubi) has been associated in postmarketing reports with serious hypersensitivity reactions including anaphylaxis and anaphylactic shock.1 Rolapitant was approved by the FDA as an oral tablet in 2015 for adjunctive prevention of delayed nausea and vomiting associated with cancer chemotherapy in adults2; the IV emulsion formulation of the drug was approved for the same indication in 2017.The reported hypersensitivity reactions occurred during or shortly after infusion of...
Fiasp - Another Insulin Aspart Formulation for Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 01, 2018 (Issue 1537)
Fiasp – Another Insulin Aspart
Formulation for Diabetes
Table 1. Rapid-Acting Insulins
Some ...
The FDA has approved Fiasp (Novo Nordisk), a new
formulation of insulin aspart, to improve glycemic
control in adults with diabetes. Fiasp is described by
the manufacturer as faster-acting than conventional
insulin aspart (Novolog).
Triptorelin (Triptodur) for Central Precocious Puberty
The Medical Letter on Drugs and Therapeutics • Jan 01, 2018 (Issue 1537)
, affecting
about 1 in 5,000-10,000 girls. Characteristics of
CPP include early breast development and start ...
The FDA has approved an extended-release
intramuscular suspension formulation of the
gonadotropin-releasing hormone (GnRH) agonist
triptorelin (Triptodur – Arbor/Debiopharm) for twice-yearly
treatment of central precocious puberty (CPP)
in children ≥2 years old. Triptorelin has been available
in the US for years as Trelstar for palliative treatment
of advanced prostate cancer. Before the approval
of Triptodur, Trelstar was used off-label for treatment of CPP.
Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness
The Medical Letter on Drugs and Therapeutics • Jan 01, 2018 (Issue 1537)
for hospitalized medical patients at
low VTE risk.1
Table 1. Pharmacology
Class Direct factor Xa inhibitor ...
The FDA has approved betrixaban (Bevyxxa –
Portola), a once-daily, oral, direct factor Xa inhibitor,
for prophylaxis of venous thromboembolism (VTE)
in adults hospitalized for an acute medical illness
who have moderately or severely restricted mobility
and other risk factors for VTE. Betrixaban is the
first oral anticoagulant to be approved in the US for
this indication.
In Brief: Pembrolizumab (Keytruda) for Cancers with Biomarkers (online only)
The Medical Letter on Drugs and Therapeutics • Jan 01, 2018 (Issue 1537)
pembrolizumab
(Keytruda – Merck), a programmed death receptor-1 (PD-
1) inhibitor, has been granted ...
The immune checkpoint inhibitor pembrolizumab (Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, has been granted accelerated approval by the FDA for use in adults and children who have unresectable or metastatic microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) solid tumors that have progressed following treatment, and do not have any satisfactory alternative treatment options. For metastatic colorectal cancer, the indication is limited to tumors that have progressed following combination treatment with a fluoropyrimidine, oxaliplatin, and...